Amarantus Bioscience (AMBS) Stock Price, News & Analysis

Company Overview

Amarantus Bioscience, Inc. is a biotechnology company that historically focused on developing therapeutics and diagnostics for neurological and other serious diseases. Its research programs centered on mesencephalic astrocyte-derived neurotrophic factor (MANF), a naturally occurring protein investigated for potential applications in disorders involving nerve-cell damage.

The company also pursued the development of NuroPro, a blood-based diagnostic platform intended to identify biomarkers associated with neurodegenerative diseases, including Parkinson’s disease. Other historical programs included drug candidates and technologies aimed at conditions such as diabetes-related complications and liver disease.

Amarantus Bioscience’s programs were primarily in the research and clinical-development stages rather than commercialized product markets. Publicly available information about its current operations, leadership, geographic reach, and development pipeline is limited, and the company’s historical activities should not be interpreted as evidence of currently marketed products or active programs.

Key Stats

• Today's Range: N/A
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: N/A
• Average Volume: 25,356 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Company Calendar

• Today: 10/15/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Healthcare
• Industry: Healthcare Providers & Services
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:AMBS
• CIK: 1424812
• Web: www.amarantus.com
• Phone: (650) 862-5391
• Fax: 408-852-4427
• Employees: 12
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: 1.74